Global Bio-CDMO market trends and growth

The biopharmaceutical Contract Development and Manufacturing Organization (Bio-CDMO) sector is experiencing significant technological and economic shifts. Contract development and manufacturing organizations are adopting flexible bioprocessing platforms to manage diverse client demands. These include integrated hardware and software solutions for upstream bioprocessing and interchangeable mesh assemblies for drug-loaded microsphere production, which aim to reduce scale-up risks and capital expenditure.

Economically, the global Bio-CDMO market is projected to reach USD 59.05 billion by 2030, with a compound annual growth rate of 12.7 percent. This expansion is driven by the rising demand for biologics, such as gene therapies and monoclonal antibodies, alongside the cost-effectiveness of outsourcing. The industry is characterized by high capital intensity and significant regulatory requirements, with major players holding approximately 49.0 percent of the market share as of 2023. Additionally, there is an increasing industry focus on sustainability, specifically regarding energy optimization, water use, and resilient supply chains.